CareLit · DOI-Nachweis · Pneumologie
Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in IPF: PANORAMA
DOI 10.1055/s-0036-1572009
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Behr, E Bendstrup, B Crestani, A Günther, H Olschewski, M Sköld, A Wells, W Wuyts, D Koschel, M Kreuter, B Wallaert, H Tang, J Beck, C Albera
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: In Europe, NAC and pirfenidone are often combined in IPF clinical practice but the safety of this combination is unknown. Method: In this randomised, double-blind, placebo (PBO)-controlled, phase 2 study, European patients on a stable dose of 1602 – 2403 mg/day pirfenidone were randomised to 24 weeks of NAC (1800 mg/day) or PBO. Adverse events (AEs) and functional parameters (spirometry, 6MWD, and SOBQ)…
Zitieren
Zitierempfehlung
J Behr, E Bendstrup, B Crestani, A Günther, H Olschewski, M Sköld, A Wells, W Wuyts, D Koschel, M Kreuter, B Wallaert, H Tang, J Beck, C Albera (2016) Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in IPF: PANORAMA. Pneumologie (02). https://doi.org/10.1055/s-0036-1572009
Mit CareLit weiterarbeiten